Skip to content
Search

Latest Stories

ABPI names Novo Nordisk’s Pinder Sahota as its new president

The Association of the British Pharmaceutical Industry (ABPI) has appointed Pinder Sahota, general manager and corporate vice president of Novo Nordisk UK as its new president.

He also chairs the Confederation of British Industries' Health Council and has previously served as vice chair of the European Medicines Group.


Effective from April 29, Sahota will lead on overseeing the ABPI, the ABPI Board, and the ABPI’s Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA). He takes over from Ben Osborn of Pfizer.

Commenting on his new role, Sahota said: “After decades of scientific investment, we are now seeing the next generation of cutting-edge treatments being made available to patients. I’m determined to use my term as President of the ABPI to make sure that new, innovative medicines reach the people who need them.

"The past two years have demonstrated just how important medicines and vaccines are to our way of life. Improving how we use new medicines can now support the NHS to recover from the pandemic by addressing the significant variations which currently exist in care across the country."

"There is a real opportunity for the UK to build on our scientific excellence and continue to help patients across the country. I look forward to working closely with the Government, NHS and colleagues across the sector to make this a reality.”

Welcoming Pinder to the role, Richard Torbett, chief executive of the ABPI, said: “I’ve hugely enjoyed working with Pinder during his time as Vice President of the ABPI, and give him a warm welcome to the Presidency from the whole ABPI.

"Pinder is a passionate advocate for the industry and brings a wealth of experience to the Presidency. I look forward to working with Pinder to deliver on the ABPI’s long term strategy to achieve our ambitions for the sector in the UK.”

More For You

NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Pharmacy First: Government confirms £215 million boost to realise its full potential

From April 2025, the consultation fee for Pharmacy First Minor Illness and Clinical Pathways will rise from £15 to £17.

‘Pharmacy First hasn't realised its full potential,’ says Stephen Kinnock

Health Minister Stephen Kinnock has acknowledged that Pharmacy First has huge potential, noting that the service “hasn't realised its full potential.”

As part of efforts to enhance the service, Kinnock yesterday (30) announced £215 million in additional funding for Pharmacy First and other Primary Care Access Recovery Plan services.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less